

















59. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. *N Engl J Med* 1988. doi: 10.1056/NEJM198802183180703
60. Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: Biological and clinical aspects. *J Thromb Haemost* 2013. doi: 10.1111/jth.12075
61. Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. *Cancer* 2007. doi: 10.1002/cncr.23062
62. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. *Blood* 2013. doi: 10.1182/blood-2013-04-460121
63. Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. *JAMA* 2005. doi: 10.1001/jama.293.6.715
64. Konstantinides SV, Meyer G, Bueno H, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). *Eur Heart J* 2020. doi:10.1093/eurheartj/ehz405
65. Chang H-M, Moudgil R, Scarabelli T, et al. Cardiovascular complications of cancer therapy. *J Am Coll Cardiol* 2017. doi: 10.1016/j.jacc.2017.09.1096
66. Reeves BN, Key NS. PL-12 acquired hemophilia in malignancy. *Thrombosis Res* 2012. doi: 10.1016/S0049-3848(12)70019-1.
67. Sallah S, Wan JY, Nguyen NP, et al. Disseminated intravascular coagulation in solid tumors: Clinical and pathologic study. *Thromb Haemost* 2001. doi: 10.1055/s-0037-1616139
68. Kozwicz DL, Kramer LC, Mielicki WP, et al. Application of cancer procoagulant as an early detection tumor marker. *Cancer* 1994. doi: 10.1002/1097-0142(19940815)74:4<1367::AID-CNCR2820740430>3.0.CO;2-Y
69. Molnar S, Guglielmo H, Lavarda M, et al. Procoagulant factors in patients with cancer. *Hematology* 2007. doi: 10.1080/10245330701521416
70. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J* 2016. doi: 10.1093/eurheartj/ehw210
71. Holmes DR, Kar S, Price MJ, et al. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: The PREVAIL trial. *J Am Coll Cardiol* 2014. doi: 10.1016/j.jacc.2014.04.029
72. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. *Lancet* 2009. doi: 10.1016/S0140-6736(09)61343-X
73. Hildick-Smith D, Landmesser U, Camm AJ, et al. Left atrial appendage occlusion with the Amplatzer™ Amulet™ device: full results of the prospective global observational study. *Eur Heart J* 2020. doi: 10.1093/eurheartj/ehaa169
74. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: A statement for healthcare professionals from the American heart association. *Circulation* 1997. doi: 10.1161/01.CIR.96.8.2751
75. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: A meta-analysis. *Am J Med* 2008. doi: 10.1016/j.amjmed.2007.10.002
76. Landolfi R, Marchioni R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. *N Engl J Med* 2004. doi: 10.1056/NEJMoa035572
77. Streiff MB, Westrom B, Ashrani A, et al. Cancer-associated venous thromboembolic disease, Version 1.2015. *J Natl Compr Cancer Netw* 2015. doi: 10.6004/jnccn.2015.0133
78. Anelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. *Lancet Oncol* 2009. doi:10.1016/S1470-2045(09)70232-3
79. Kaplan E. Venous thromboembolic disease. In: C.J. Wong, N.P. Hamli, editors. *The perioperative medicine consult handbook*. New York: Springer. 2015.
80. Khorana A, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. *Blood* 2008. doi: 10.1182/blood-2007-10-116327

Non-commercial use only